|
1 |
Neuropsychiatric manifestations of primary hyperparathyroidism
Enthalten in Wiener klinische Wochenschrift 8.1.2026: 1-9
|
|
|
2 |
Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
Oliva, Vincenzo. - Freiburg : Universität, 2025
|
|
|
|
3 |
Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis
Enthalten in European archives of psychiatry and clinical neuroscience 11.8.2025: 1-16
|
|
|
|
4 |
Correction: Mild motor signs and depression: more than just medication side effects?
Enthalten in European archives of psychiatry and clinical neuroscience 21.5.2025: 1
|
|
|
|
5 |
Mild motor signs and depression: more than just medication side effects?
Enthalten in European archives of psychiatry and clinical neuroscience 25.4.2025: 1-7
|
|
|
|
6 |
Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers
Möller, Hans-Jürgen. - Würzburg : Universität Würzburg, 2024
|
|
|
|
7 |
Die Rolle von Phytotherapie bei COVID-19-assoziierter Angst und Depression
Enthalten in Zeitschrift für Phytotherapie Bd. 45, 2024, Nr. 04: 148-156
|
|
|
|
8 |
Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data
Enthalten in European archives of psychiatry and clinical neuroscience 25.10.2024: 1-15
|
|
|
|
9 |
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Enthalten in Wiener klinische Wochenschrift 17.4.2024: 1-14
|
|
|
|
10 |
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Enthalten in European archives of psychiatry and clinical neuroscience 1.4.2024: 1-11
|
|
Administration
